Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Link
http://link.springer.com/article/10.1007/s11899-017-0385-y/fulltext.html
Reference40 articles.
1. Noordijk EM, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol. 2005;23(16_suppl):6505–6505.
2. Engert A, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–52.
3. •• Radford J, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–607. UK NCI RAPID response-adapted trial. Addition of RT to ABVD × 4 for PET negative patients resulted in 6% improvement in 3-year EFS.
4. •• Andre ́ M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017. doi: 10.1200/JCO.2016.68.6394 . Patients with early-stage favorable and unfavorable HL with negative interim PET following ABVD randomized to ± XRT. Radiotherapy randomization stopped early by DSMC when significant improvement in PFS demonstrated with CMT.
5. Meyer RM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399–408.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Extranodal lymphoma: pathogenesis, diagnosis and treatment;Molecular Biomedicine;2023-09-18
2. Evolution in the Presence and Evidence Category of Radiation Therapy Treatment Recommendations in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology;Advances in Radiation Oncology;2023-07
3. The “Hand as Foot” memorizing method in the radiation field of Hodgkin lymphoma;Asian Journal of Surgery;2022-10
4. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2021-02
5. Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma;JCO Oncology Practice;2021-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3